Saturday 17 October 2026
Export ANIK’s income statement to Excel — free account
Anika Therapeutics Inc.
ANIK Healthcare Drug Manufacturers Specialty & Generic
Anika Therapeutics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $112.8 million, down 5.91% from fiscal 2024. In the quarter to June 2026, revenue grew 15.6%, EPS grew 189.3% and free cash flow grew 61.6%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
19.98
0.71
−3.43%
Follow ANIK
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
1.20 | 1.22 | 1.69 | 1.62 | |
P/FCF ratio |
108.60 | 27.77 | 0.00 | 347.01 | |
P/Operating CF |
19.73 | 29.72 | (40.49) | (285.11) | |
P/B ratio |
0.92 | 0.96 | 1.47 | 1.42 | |
Price to Tangible BV |
0.99 | 1.03 | 1.58 | 1.53 | |
EV/Sales |
0.91 | 0.93 | 1.55 | 1.51 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 354.70 | |
EV/Operating CF |
12.61 | 9.41 | 27.84 | 30.38 | |
EV/FCF |
82.17 | 21.22 | (63.07) | 323.14 | |
Quick Ratio |
4.20 | 3.71 | 3.19 | 3.05 | |
Current Ratio |
5.32 | 4.72 | 4.46 | 4.48 | |
Net Debt/EBITDA |
31.69 | (29.27) | 10.05 | (8.61) | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.54 | 0.57 | 0.63 | 0.65 | |
Operating CF/Net income |
(2.95) | 15.88 | 0.96 | (0.21) | |
Capex/Depreciation |
(1.34) | (0.49) | (1.02) | (0.96) | |
Research and Development Expense of Revenue |
24.97% | 21.07% | 22.67% | 22.51% | |
Selling, General and Administrative Expense of Revenue |
42.68% | 39.46% | 60.02% | 33.58% | |
Intangible Assets out of Total Assets |
0.05 | 0.05 | 0.05 | 0.05 | |
Share Based Compensation of Revenue |
7.96% | 8.03% | 22.43% | 5.62% | |
Graham Net Nets |
0.44 | 0.41 | 0.25 | 0.27 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(24.26%) | (7.91%) | (5.45%) | (1.78%) | |
Free Cash Flow Yield |
0.92% | 3.60% | (1.46%) | 0.29% | |
Revenue per Share |
1.93 | 2.14 | 2.19 | 2.45 | |
Operating CF per Share |
0.48 | 0.32 | (0.36) | (0.05) | |
Capex per Share |
(0.13) | (0.05) | (0.11) | (0.11) | |
Free Cash Flow per Share |
0.35 | 0.28 | (0.46) | (0.16) | |
Cash per Share |
4.02 | 4.01 | 3.03 | 2.88 | |
Shareholders Equity per Share |
10.18 | 10.01 | 9.90 | 10.30 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
10.18 | 10.01 | 9.90 | 10.30 | |
Free Cash Flow |
4.98 | 3.99 | (6.28) | (2.13) | |
Working Capital |
82.50 | 81.45 | 72.60 | 77.04 | |
Capital Expenditures |
(1.89) | (0.65) | (1.43) | (1.45) | |
Net Current Asset Value |
58.96 | 56.55 | 48.08 | 53.00 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.07 | 0.02 | 0.05 | 0.04 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
25.27 | 23.64 | 23.88 | 26.51 | |
Average Payables |
5.77 | 5.83 | 5.81 | 5.50 | |
Average Inventory |
27.96 | 21.30 | 22.09 | 22.74 | |
Average Assets |
210.42 | 196.51 | 185.00 | 185.58 | |
Average Common Equity |
163.33 | 148.73 | 141.15 | 142.48 |
Columns are period end dates